Literature DB >> 18033186

[Lung cancer in women and pregnancy: towards a hormonal origin?].

J Mazières1, I Rouquette, L Brouchet.   

Abstract

INTRODUCTION: The incidence of lung cancer is increasing dramatically in women in France. It is now the leading cause of cancer deaths among women in the USA and the second in France. STATE OF THE ART: Lung cancer occurring in women displays some specific epidemiological, radiological, clinical and pathological characteristics. Moreover, both prognosis and response to treatment appear to be different from men. In line with these findings, lung carcinogenesis is, at least in part, distinct in women and involves different mechanisms and signalling pathways. We emphasize in this review genetic and hormonal specificities based upon epidemiological and biological studies. Moreover, we focus on lung cancer developing during pregnancy by reporting an individual case and discussing the published literature. PERSPECTIVES AND
CONCLUSIONS: Recent works suggest that lung cancer in women is a distinct entity with specific carcinogenesis. We propose that a better knowledge of this entity will permit the identification of specific genetic alterations or hormonal profiles that may serve as new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18033186     DOI: 10.1016/s0761-8425(07)92763-1

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  3 in total

Review 1.  [Small cell bronchial carcinoma and pregnancy: about a case with review of the literature].

Authors:  Fatima Safini; Hassan Jjouhadi; Asmaa Chehal; Farida Mernissi; Akpoo Wilfried; Zineb Bouchbika; Amina Taleb; Nadia Benchakroun; Nezha Tawfiq; Souha Sahraoui; Abdellatif Benider
Journal:  Pan Afr Med J       Date:  2016-03-25

Review 2.  [Advances of targeted therapy based on estrogen receptor signaling pathway in lung cancer].

Authors:  Liqiang Xu; Yongde Liao; Hexiao Tang; Chao Zhang; Zhaoguo Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-09

3.  Fulvestrant-mediated inhibition of estrogen receptor signaling slows lung cancer progression.

Authors:  Hexiao Tang; Yongde Liao; Chao Zhang; Guang Chen; Liqiang Xu; Zhaoguo Liu; Shengling Fu; Li Yu; Sheng Zhou
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.